Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia.
Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia.
Nephrology (Carlton). 2023 Jun;28(6):328-335. doi: 10.1111/nep.14160. Epub 2023 Apr 19.
Predicting progression to kidney failure for patients with chronic kidney disease is essential for patient and clinicians' management decisions, patient prognosis, and service planning. The Tangri et al Kidney Failure Risk Equation (KFRE) was developed to predict the outcome of kidney failure. The KFRE has not been independently validated in an Australian Cohort.
Using data linkage of the Tasmanian Chronic Kidney Disease study (CKD.TASlink) and the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), we externally validated the KFRE. We validated the 4, 6, and 8-variable KFRE at both 2 and 5 years. We assessed model fit (goodness of fit), discrimination (Harell's C statistic), and calibration (observed vs predicted survival).
There were 18 170 in the cohort with 12 861 participants with 2 years and 8182 with 5 years outcomes. Of these 2607 people died and 285 progressed to kidney replacement therapy. The KFRE has excellent discrimination with C statistics of 0.96-0.98 at 2 years and 0.95-0.96 at 5 years. The calibration was adequate with well-performing Brier scores (0.004-0.01 at 2 years, 0.01-0.03 at 5 years) however the calibration curves, whilst adequate, indicate that predicted outcomes are systematically worse than observed.
This external validation study demonstrates the KFRE performs well in an Australian population and can be used by clinicians and service planners for individualised risk prediction.
预测慢性肾脏病患者向肾衰竭进展对于患者和临床医生的管理决策、患者预后和服务规划至关重要。Tangri 等人开发的肾衰竭风险方程(KFRE)用于预测肾衰竭的结果。KFRE 尚未在澳大利亚队列中进行独立验证。
我们通过塔斯马尼亚慢性肾脏病研究(CKD.TASlink)和澳大利亚和新西兰透析和移植登记处(ANZDATA)的数据链接对 KFRE 进行了外部验证。我们在 2 年和 5 年时验证了 4、6 和 8 变量 KFRE。我们评估了模型拟合(拟合优度)、区分度(Harell's C 统计量)和校准(观察与预测生存)。
队列中有 18070 人,其中 12861 人有 2 年的结果,8182 人有 5 年的结果。其中 2607 人死亡,285 人进展为肾脏替代治疗。KFRE 在 2 年时的 C 统计量为 0.96-0.98,在 5 年时为 0.95-0.96,具有极好的区分度。校准是充分的,Brier 评分表现良好(2 年时为 0.004-0.01,5 年时为 0.01-0.03),但是校准曲线虽然充分,但表明预测结果比观察结果系统地差。
这项外部验证研究表明,KFRE 在澳大利亚人群中表现良好,临床医生和服务规划者可以使用它进行个体化风险预测。